SIONSionna Therapeutics Inc. Common Stock
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-dire…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead Don't bet against Vertex Pharmaceuticals in cystic fibrosis. | ||
 Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep? Sionna Therapeutics (SION) is back in focus after reporting topline results for its cystic fibrosis programs, including a Phase 2a proof of concept miss for SION-719 and supportive Phase 1 data for SION-451 combinations. See our latest analysis for Sionna Therapeutics. The Phase 2a miss for SION-719 triggered a sharp reset in sentiment, with Sionna Therapeutics’ share price down 86.8% over the past week and 84.1% year to date. The 1-year total shareholder return has declined 70.1%, indicating... | ||
Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed? Sionna Therapeutics recently reported that its lead cystic fibrosis candidate SION-719 failed to meet the key activity endpoint in a Phase 2a proof-of-concept trial as an add-on to Trikafta, prompting the company to stop further development in this setting. At the same time, early-stage data supported advancing SION-451 in combination with SION-2222 while management moves to preserve a roughly US$268.30 million cash balance and reassess the pipeline. We will now examine how discontinuing... | ||
Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provid | MMT Newswires | |
Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall Sionna Therapeutics stock has fallen sharply in recent sessions, yet the valuation checks suggest it is not a clear bargain even after the sell off. The share price reset sits alongside a low overall value score and a mixed read on what investors are paying for the business today. The stock declined 89.8% over the past week, which signals a major reset in market expectations after recent news. The failure of lead cystic fibrosis candidate SION-719 in a Phase 2a trial can weigh heavily on... | ||
 One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial failure, while Vertex Pharmaceuticals (NASDAQ:VRTX), the company whose drug dominance Sionna was attempting to challenge, surged to new highs. The Pipeline Flop Sionna […] | IInsider Monkey | |
 Sionna Therapeutics stock falls 92% after SION-719 trial failure The biotech said it will not advance SION-719 as an add-on therapy after the drug missed its key endpoint in a Phase 2a study | ||
 Sionna Therapeutics (SION) Halts Lead Cystic Fibrosis Drug After Phase 2 Failure Sionna Therapeutics (NasdaqGM:SION) reported that its lead cystic fibrosis drug candidate failed a Phase 2 trial. The company has halted further development of the candidate and is redirecting resources to other pipeline programs. The outcome removes a potential new competitor to existing cystic fibrosis treatments and marks a major shift in Sionna Therapeutics’ priorities. This kind of abrupt change in a single biotech can be a reminder to also look at more resilient, lower-risk stocks... | ||
 Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path Sionna Therapeutics (NASDAQ:SION) said its PreciSION CF Phase 2a proof-of-concept study of SION-719 added to Trikafta did not meet its key activity endpoint, prompting the company to discontinue development of SION-719 as an add-on to standard of care for cystic fibrosis. The company also reported | ||
 Immunic appoints Elena Ridloff to board of directors Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Elena Ridloff to its board of directors, the biotechnology company said Monday. Ridloff currently serves as CFO at Sionna Therapeutics. She previously held the same role at ACADIA Pharmaceuticals, where she helped raise $600 million in capital and... | ||
 Why Vertex Pharma Popped, As A Key Rival Plummeted 92% Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment. | ||
 Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals. | ||
Sector Update: Healthcare Stocks Rise in Afternoon Trading Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State | MMT Newswires | |
 SION Stock On Track For Worst Day Ever After 90% Drop — What’s Driving The Selloff? Sionna said on Monday that its mid-stage trial of SION-719 in 15 adults with cystic fibrosis already taking Vertex’s Trikafta failed to meet its main goal. | ||
Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails Sionna's disappointing trial removes an immediate competitive threat to the franchise generating most of Vertex's revenue. | ||
Top Midday Stories: Intel Offers $15 Billion of Common Stock; Microsoft to Ramp Up Production of Homegrown AI Chip Stocks were relatively flat on Monday, as investors await further developments on the status of nego | MMT Newswires | |
 Tenax, Sionna Shares Sink After Trial Failures Shares of Tenax Therapeutics and Sionna Therapeutics tumbled Monday after the biotechs revealed separate late-stage trial failures. Tenax stock fell nearly 90% after a Phase 3 trial of its experimental heart-failure pill failed to help patients walk farther than those on a placebo. | ||
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Monday Amid Rising Oil Prices The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively tr | MMT Newswires | |
 Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire? This risk is weighing on the stock. | ||
 How Vertex Regained Its Footing On A Competitor's Bullish Report Vertex stock regained its footing Tuesday, rising on a strong second-quarter report and amid heightened expectations for its kidney disease treatment. | ||
Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says Vertex Pharmaceuticals (VRTX) reported a solid Q2 and raised its outlook, highlighting the strength | MMT Newswires | |